In recent years, manufacturing technologies for peptides and oligonucleotides have advanced considerably; however, research and development efforts have remained predominantly focused on upstream processes, particularly synthetic methodologies. In industrial practice, downstream operations, including purification and lyophilization, often constitute major bottlenecks to productivity, and meaningful, sustainable improvements at scale are unlikely without technological innovation in these areas. To address this challenge, we have focused our efforts on developing downstream processes beyond purification, with an emphasis on continuous purification and mixer-type lyophilization technologies. In this study, we describe the key features of these two technologies and evaluate their implementation in the large-scale manufacturing of a cyclic peptide, in comparison with conventional approaches. Application of these technologies resulted in an approximately 1.5-fold increase in overall yield and improvements in product quality. Additionally, the time required for downstream processing was reduced to nearly one-quarter of that associated with the traditional workflow. Collectively, these findings demonstrate that innovation in downstream operations can substantially enhance both productivity and product quality in peptide and oligonucleotide manufacturing.
Ochi et al. (Fri,) studied this question.